Preclinical studies with alvocidib (a cyclin-dependent kinase inhibitor) and bortezomib (a proteasome inhibitor) have shown that these agents interact synergistically to induce apoptosis in malignant hematopoietic cells. The clinical relevance of this finding for patients with B-cell neoplasms was previously tested in a phase I trial in which the dose-limiting toxicities (DLTs) and maximum tolerated dose of the combination of these agents was determined, with alvocidib administered by a "hybrid", pharmacologically-derived infusional schedule. The phase I trial described here extends this study by administering alvocidib according to a standard and considerably more easily managed bolus schedule. Here, we report that the two regimens were associated with similar toxicity and response profiles, including responses in patients who had previously progressed following bortezomib treatment. Consequently, based on the results of the present trial, the non-hybrid dosing schedule is recommended for subsequent phase II evaluation. The most common non-hematologic toxicities included diarrhea, fatigue, and sensory neuropathy. Three complete remissions (8%) and 10 partial remissions (26%) were observed for a total response rate of 33%. Pharmacokinetic findings with the current dosing regimen were consistent with the comparable literature and the hybrid dosing regimen. Pharmacodynamic study results did not correlate with clinical responses.
Introduction
Despite numerous therapeutic options (e.g., cytotoxic chemotherapy, monoclonal antibodies, radioimmunotherapy, and combinations thereof) for patients with indolent B-cell nonHodgkin lymphoma (NHL), cures largely remain elusive. Allogeneic stem cell transplantation (SCT) using reduced-intensity conditioning (RIC) regimens, which carry a lower treatmentrelated mortality (TRM) risk than myeloablative regimens, can theoretically produce cures via a graft-versus-lymphoma effect, but definitive evidence of efficacy of this strategy is lacking (1) .
Similarly, while proteasome inhibitors and immunomodulatory drugs have dramatically altered the therapeutic landscape in multiple myeloma (MM), the disease remains incurable aside from allogeneic SCT. Although RIC regimens have lowered the high TRM-associated with myeloablative conditioning, convincing evidence is lacking that allogeneic SCT improves survival compared with autologous SCT, and the former is only recommended in the context of clinical trials (2) . Novel therapeutic approaches are, therefore, clearly needed for patients with these diseases.
Bortezomib, the first-in-class proteasome inhibitor, received regulatory approval in the United States in 2003 after large phase II and III trials demonstrated promising single-agent activity in patients with relapsed or refractory MM (3, 4) . Its mechanism of action (MOA) is partly mediated through nuclear factor-kappa B (NF-κB) inhibition that results in apoptosis, decreased angiogenic cytokine expression, and interference with the tumor microenvironment. Additional
MOAs include c-Jun N-terminal kinase activation and growth factor expression modulation (5).
Subsequent combination phase III studies established the drug for frontline MM therapy (6) .
Based on a 33% response rate in a large multicenter phase II trial (7), bortezomib was also approved for patients with relapsed or refractory mantle cell lymphoma (MCL). More recently, regimens combining bortezomib with chemoimmunotherapy have yielded high response rates (83-88%) in patients with relapsed/refractory indolent B-cell NHL and MCL (8, 9) . Author Manuscript Published OnlineFirst on September 23, 2014; DOI: 10.1158/1078-0432.CCR- As perturbations of the cell cycle are almost universal in human malignancies, the cyclindependent kinases (CDKs) have become attractive targets for cancer therapy (10, 11) . Alvocidib (flavopiridol), the first CDK inhibitor to enter the clinic, globally represses transcription by non-ATP-competitive inhibition of positive transcription elongation factor b (P-TEFb, CDK9/cyclin T1) (12) , inducing down-regulation of the short-lived anti-apoptotic protein myeloid cell leukemia-1 (Mcl-1), which may represent the drug's principal MOA in malignant hematopoietic cells (13).
Indeed, in MM cells, for which Mcl-1 is an essential survival protein (14) , alvocidib induces apoptosis through Mcl-1 transcriptional repression and down-regulation (15) .
Alvocidib has been administered via a variety of schedules (10, 11) . While the singleagent activity in patients with MCL or MM using 1-hour intravenous bolus administration was modest to nonexistent (16, 17) , marked clinical efficacy was noted in studies in patients with genetically high-risk chronic lymphocytic leukemia (CLL) using a pharmacologically-derived "hybrid" administration schedule (18, 19) . However, hybrid schedule results were disappointing in a phase I trial in patients with relapsed/refractory acute leukemias (20) . Similarly, hybrid dosing did not improve results compared to a 1-hour bolus infusion in a phase I trial of alvocidib, fludarabine, and rituximab that reported an overall response rate of 82% in patients with MCL, B-NHL, or CLL (21) . Finally, a recent randomized phase II comparison of bolus and hybrid dosing of alvocidib (followed sequentially by cytarabine and mitoxantrone) in patients with newly diagnosed poor-risk acute myeloid leukemia (AML) showed comparably encouraging results for both schedules, prompting selection of a bolus administration for successor studies (22) .
Malignant cells are highly susceptible to a strategy in which survival signaling and cell cycle regulatory pathways are simultaneously disrupted (23) . Furthermore, Mcl-1 accumulation is an undesirable molecular consequence of proteasome inhibitor exposure, attenuating proapoptotic effects, and arguing that targeting Mcl-1 may increase the effectiveness of these agents (24) . In support of these concepts, bortezomib and alvocidib interact synergistically to induce apoptosis in various leukemic cells (25, 26) . In this context, alvocidib also inhibits IκB kinase, and by extension, NF-κB (27) , and in this way may cooperate with bortezomib in triggering malignant hematopoietic cell death (26) .
Given these observations, a multicenter phase I trial of this novel drug combination was initiated in patients with recurrent or refractory B-cell neoplasms. Patients received bortezomib by intravenous push followed by a 1-hour infusion of alvocidib on days 1, 4, 8, and 11. Based on encouraging results in the CLL trial (18, 19) , a hybrid schedule of alvocidib as a 30-minute bolus infusion followed by a 4-hour infusion on days 1 and 8 was explored and MTD determined (28) .
During this time the original non-hybrid schedule of this trial was put on hold without reaching the MTD and accrual was resumed after completion of the hybrid schedule (28) . The results of the original non-hybrid schedule are described in this manuscript.
Research. 
Patient eligibility
Patients must have had a diagnosis of relapsed or refractory follicle center lymphoma (follicular or diffuse), mantle cell lymphoma (MCL), marginal zone B-cell lymphoma (splenic, nodal or extranodal), lymphoplasmacytoid lymphoma/immunocytoma, plasma cell myeloma, plasmacytoma, plasma cell leukemia, or Waldenstrom's macroglobulinemia with no potential curative therapeutic options . Patients with a history of a central nervous system involvement were ineligible. Prior autologous SCT, but not prior allogeneic SCT, was allowed. Prior bortezomib was also allowed. 
Treatment plan
This study was designed as a phase I, nonrandomized, dose-escalation study to determine the MTD for the bortezomib and alvocidib combination, where alvocidib is administered as a 1-hour infusion. was administered via intravenous push over 3 to 5 seconds, after which alvocidib was administered as an intravenous infusion over 1 hour. Treatment was repeated every 3 weeks. 
Study design, definition of dose-limiting toxicity, and identification of the MTD
The standard 3+3 dose-escalation design was used, with a dose level expansion of up to 6 evaluable patients if a dose-limiting toxicity (DLT) was noted. The MTD was defined as the highest dose level at which fewer than 2 of 6 patients experienced a DLT.
A DLT was initially defined as any of the following occurring during the first cycle of treatment and determined to be possibly, probably, or definitely related to study treatment: (1) 
Response evaluation
Response criteria used were based on the nature of the disease as follows: (a) patients with lymphomas were evaluated using the NCI-sponsored Working Group Lymphoma Response Criteria (29) 
Alvocidib pharmacokinetic studies
Samples from the first 29 enrolled patients were obtained for alvocidib pharmacokinetic analysis. The samples were obtained prior to and following treatment on Cycle 1 Day 1 and 
Enrichment of CD138 + MM cells from bone marrow
Paired bone marrow aspirates were obtained from MM patients only: (1) prior to initial study treatment, and (2) on Day 2 of Cycle 1, approximately 24 hours following initial treatment.
CD138
+ MM cells were enriched from bone marrow as previously described (28) .
Protein extraction and Western blot analysis
Research. Protein extraction and Western blot analyses with primary antibodies to pJNK, Mcl-1, XIAP, and GAPDH were done as previously described (28) . A PARP-specific antibody (BD Pharmingen) was also included. An Odyssey Imager (LI-COR Biosciences) was used to quantify binding of IRDye 680LT-conjugated secondary antibodies (LI-COR Biosciences).
Localization and quantitative immunofluorescence of p65/RelA
RelA belongs to a family of transcription factors of NF-kappa-B complex. Cytospin preparations of enriched CD138 + plasma cells were prepared from study patients before and during treatment. The cells were fixed, stained, and visualized by fluorescence microscopy as previously described (28) . Analysis of NF-kB within the nucleus was performed using the Definiens® Developer v1.5 software suite (Definiens, Munich, Germany). The nuclear region was determined with automatic threshold segmentation on the DAPI and Alexa 488 stains;
further refined for plasma cells by the size and shape of the nuclei. Mean pixel intensity of the Alexa 488 signal was determined from the nuclei of the plasma cells.
Statistical analysis
Basic demographics, adverse events, DLTs, dose levels, clinical responses were summarized by basic descriptive statistics such as frequency, proportion, mean, median, and range. Pharmacokinetic and pharmacodynamic analyses including all biomarkers and p65/ReIA were limited to descriptive statistics.
Human investigation studies
Studies were performed after Institutional Review Board approval and in accordance with an assurance filed with and approved by the Department of Health and Human Services.
Informed consent was obtained from each patient. ClinicalTrials.gov trial registration ID:
NCT00082784.
Research. Hispanics) and 9 African-Americans (including 1 Hispanic). Median age of patients was 64.5 years (range: 40-79). Twenty-four patients were diagnosed with MM, 2 were diagnosed with Waldenstrom's macroglobulinemia (WM), and 18 were diagnosed with NHL (5 of whom had MCL, an NHL subset). The median number of prior treatments was 3, with a range of 1 to 10.
Ten patients had received prior autologous SCT and 10 patients had prior bortezomib therapy.
Patients received a median of 5 cycles of study treatment, with a range of 1-16 cycles.
Safety and tolerability
Myelosuppression was a common hematologic toxicity and typically manifested itself as grade 3 leukopenia (30%), lymphopenia (25%), neutropenia (34%), or thrombocytopenia (27%) ( Table 2 ). Grade 4 neutropenia (23%) and thrombocytopenia (14%) were also commonly observed. The most common non-hematologic toxicities included grade 3 diarrhea (20%) and fatigue (16%). Grade 3 pain and grade 3 sensory neuropathy were slightly less commonly experienced. One patient experienced grade 4 sensory neuropathy. A patient with follicular lymphoma developed grade 3 oral mucositis/esophagitis (which lasted more than 7 days) on Day 2 of Cycle 1, associated with both paraneoplastic pemphigus and a grade 4 CD4 lymphocyte count without HIV infection. The patient's prior treatment regimen was rituximab and bendamustine. The most common grade 2 hematologic and non-hematologic toxicities, occurring in at least 20% of patients are listed in Table 2 . Prior to initiation of prophylactic antiviral treatment with acyclovir or comparable agents, 2 patients experienced grade 3 herpes zoster.
DLT and MTD
Research. In the initial enrollment phase to the non-hybrid schema, 1 DLT was seen at dose level 5, necessitating expansion to 6 DLT-evaluable patients (Table 3) . No other DLTs were noted in that expansion cohort. Patient enrollment continued through 3 DLT-evaluable patients at dose level 7 before the trial was interrupted and switched to the evaluation of the hybrid schema.
Upon return to the non-hybrid schema, the 3+3 dose-escalation design of the study allowed progression through dose level 9. DLT accumulation at subsequent higher dose levels required a de-escalation to lower dose levels until the MTD was reached at dose level 5. 
Disease response
Although this study was not powered to assess response, 3 complete responses (CRs) and 10 partial responses (PRs) were observed among the 39 patients evaluable for response (overall response rate = 33%; Table 4 ). The overall response rate was similar for both NHL patients (33%) and MM patients (32%), with a 50% response rate in a limited sample of patients with WM. CRs were experienced by 2 (one of whom had mantle cell lymphoma) of the 15 NHL patients (13%) and 1 of the 24 MM patients (4%). The MM patient with the CR had previously been treated with bortezomib. PRs were achieved in 26% of the patients-3 with NHL (20%), 6
with MM (27%), and 1 with WM (50%). A total of 20 patients had stable disease (SD) as best
response and 6 patients had progressive disease (PD). Among the patients not evaluable for response, 3 patients came off treatment for adverse events prior to the disease assessment interval, 1 patient came off treatment in Cycle 1 due to a second cancer (renal) and did not have a response assessment, and 1 patient came off treatment in Cycle 1 for convenience (moved far from the treatment center) and did not have response assessment
Pharmacokinetic studies
Samples were collected from the first 29 patients enrolled to the non-hybrid schedule.
Alvocidib pharmacokinetics were evaluated using a non-compartmental (model-independent) approach. A sample immediately at the end of the 1-hr alvocidib infusion was only collected in 11 of the 29 patients. Consequently, a C MAX could be reported for these 11 patients. Of these 11 patients, only 9 had sufficient data to calculate a terminal elimination rate for the determination of half-life, clearance, and AUC INF . No lag in peak alvocidib concentration (C MAX ) was observed.
Maximum alvocidib concentration was observed immediately at the end of the infusion (Supplemental Fig. 1 ). Cycle 1 Day 1 alvocidib pharmacokinetic parameters per dose level are shown in Supplemental Table 1 .
Pharmacodynamics
To determine the feasibility of measuring pharmacodynamic markers as a predictor of response, pre-and post-treatment samples (24 hours after the first doses of drugs) were obtained from the MM patients for quantitative analysis of p65/RelA nuclear localization by immunofluorescence staining (Fig. 1) and for quantitative analysis of pJNK, Mcl-1, PARP, and XIAP by Western blotting (Fig. 2) . Changes in expression of these proteins were previously observed in cells co-exposed to alvocidib and bortezomib in vitro (25) .
Cytospin preparations of enriched CD138
+ plasma cells were prepared from the pre-and post-treatment bone samples from 8 MM patients including 2 patients from the PR group (DS027 and DS046), 5 patients from the SD group (DS011, DS047, DS050, DS055, and
SG015), and 1 patient from the PD group (DS023). NF-κB activation was measured by
Discussion
In the original study of the alvocidib/bortezomib regimen initiated in March 2004, 29 patients were first enrolled to the non-hybrid schedule at dose levels 1-7 without reaching the MTD. In 2007, the protocol underwent a CTEP-recommended amendment to proceed to a hybrid schedule based on promising data in CLL (19) . Results from the hybrid schedule trial have been published (28) . A total of 16 patients were treated, consisting of 11 male and 5 female patients. Nine patients had NHL (6 patients had mantle cell lymphoma subtype), 6 had multiple myeloma, and 1 had an extramedullary plasmacytoma. Treatment was on a 21- on a 21-day cycle (Table 3) . In a previous hybrid study of these agents in the same patient population, the MTD was found to be 1.3 mg/m 2 of bortezomib (intravenous push) on days 1, 4, The most common hematologic toxicities for both the current and previous study involved myelosuppression (including grade 3 leukopenia and lymphopenia) and grades 3 and 4 neutropenia and thrombocytopenia [ Table 2 and reference (28)]. Likewise, the non-hematologic toxicity profile for both studies was very similar with grade 3 diarrhea, fatigue, and sensory neuropathy most frequently reported. One of the DLTs in the current regimen was grade 3 laboratory TLS in 1 patient with Waldenstrom's Macroglobulinemia at dose level 7 ( Table 2 ).
The event was managed with IV fluids and laboratory abnormalities normalized within 12 hours.
This patient received a total of 6 cycles of the treatment and achieved a PR. No TLS was observed with the hybrid schedule (28) . DLTs for both studies included grade 3 fatigue and febrile neutropenia, while the previous study also reported a single case of grade 3 aspartate aminotransferase elevation. Two patients on the present study developed herpes zoster (Table   2 ), but no additional episodes were reported following prophylactic antiviral therapy. Similarly, no episodes of herpes zoster were reported in the hybrid study, which included prophylactic antiviral therapy. (28) . Patients received a median of 5 cycles of treatment on the current study (Table 1 ) compared to a median of 4 cycles of treatment on the previous study (28) . Thus, both study regimens displayed a similar safety profile.
Although the primary objective of this phase I study was not to determine the efficacy of the treatment regimen, 3 CRs (NHL = 2, MM = 1) and 10 PRs (NHL = 3, MM = 6, WM = 1) were observed for an overall CR+PR response rate of 13 patients out of 39 evaluable patients (33%) ( Table 4) . This compares to an overall CR+PR response rate of 7 patients out of 16 evaluable patients (total = 44%, NHL = 33%, MM = 57%) in the previous study of the hybrid regimen (28) .
As the MM patient in the present study who achieved a CR had previously progressed on bortezomib, this raises the possibility that either alvocidib exhibited single agent activity, or, as previously observed in in vitro studies (25) , it may have cooperated with bortezomib to lower the cell death threshold. Previously reported response rates for bortezomib as a single agent in relapsed/refractory disease are approximately 33% for MCL (7), 35% MM (3), and 13.3% for indolent NHL including follicular lymphoma, marginal zone lymphoma, and small lymphocytic lymphoma (33) . Because this study was not powered to characterize efficacy, firm conclusions about the activity of the combination of bortezomib and alvocidib in comparison to bortezomib as a single agent cannot be drawn. Nevertheless, the response rates in this phase I trial, which involved multiply-treated relapsed/refractory patients, are encouraging and warrant further study.
This non-hybrid schedule produced comparable pharmacokinetic parameter values as the hybrid schedule (28) . Furthermore, the pharmacokinetics of the non-hybrid schedule were consistent with published results using 1-hr infusion schedule (34) . Alvocidib pharmacokinetics in the absence of bortezomib were not evaluated in this clinical trial. Consequently, direct comparison cannot be made. However PK parameters are in very close agreement with a previous study (34, 35) for dose-normalized CMAX, dose-normalized AUC, half-life, and clearance. Together, these results suggest that the administration of bortezomib immediately prior to the alvocidib infusion does not affect its disposition.
Based on previous findings demonstrating that bortezomib and alvocidib interact synergistically to induce apoptosis in human leukemia cells (25, 26) , it was plausible to postulate that co-administration of these agents in vivo to patients with B-cell malignancies (Fig. 1) . Similarly, among the 4 paired samples (all SD) analyzed by Western blot, and despite the fact that single-agent alvocidib has been shown to diminish Mcl-1 expression (37), only one sample showed a decrease in expression. While this result was unanticipated, it is possible that in this instance, diminished
Mcl-1 proteasomal degradation may have predominated. Although a major mode of action of the bortezomib/alvocidib regimen is presumed to be apoptosis induction, only sample SG015 (from a patient with SD) displayed enhanced post-treatment PARP cleavage. Whether the inconclusive results seen here reflect the small sample size, differing drug doses, or the possibility that these molecules may not be robust markers of therapeutic activity cannot be determined in the context of this phase I trial. While bone marrow sampling was mandatory for patients with myeloma, it proved logistically cumbersome, thereby limiting the number of samples obtained. These questions could possibly be answered in more a more highly powered phase II trial with larger patient numbers and more uniform drug dosing.
In conclusion, this phase I study has determined the MTD for the combination of bortezomib and alvocidib administered as a 1-hour infusion in patients with recurrent or refractory indolent B-cell cancers. Both the observed hematologic and non-hematologic toxicities were similar to those observed with bortezomib as a single agent combined with a hybrid dose schedule of alvocidib (28) . The dosing regimen employed here resulted in 3 CRs The protocol underwent a mandatory amendment at dose level 7 (prior to reaching the MTD of the pre-hybrid schedule) to pursue a hybrid dosing schedule (28) . After determining the MTD of the hybrid-dosing schedule, accrual resumed to the pre-hybrid dosing schedule at dose level 8. Patients were enrolled through dose level 9, when DLTs required retrograde expansion of dose levels 8 through 6 in order to find the MTD of the pre-hybrid schedule. Excluded from the totals are 5 patients who were not evaluable for response: 3 patients came off treatment for adverse events prior to the disease assessment time point, 1 patient came off treatment in Cycle 1 due to a second cancer (renal mass) and did not have a response assessment, and 1 patient came off treatment in Cycle 1 for convenience (moved a far distance from the treatment center) and did not have a response assessment. 
